As shown in the results, combination of LSD1 inhibitor with anti-PD1 antibody showed significant superior therapeutic advantages compared with single-treatment groups in both suppressing tumour growth and metastasis, and prolonging overall survival (Fig. 6h–j and Supplementary Fig. 8e–g). The gene discussed is PDCD1; the disease is neoplasm.